[Efficacy and safety of GLP-1 receptor agonists combined with bariatric surgery for obesity: a timing-stratified systematic review].
GLP-1 drugs help people who regain weight after bariatric surgery lose an additional 10% body weight on average versus standard care.
To systematically evaluate the efficacy and safety of GLP-1 receptor agonists applied at different stages before and after bariatric surgery, and to compare the clinical benefits of preoperative use, early postoperative use, and rescue use after insufficient weight loss or weight regain according to medication timing. For rescue therapy, four randomized controlled trials showed that GLP-1 receptor agonists ed in an additional 10.30 percentage points of endpoint percentage weight loss compared with placebo or usual care (95%CI: 6.40-14.20, I² =89.2%, P <0.05).
What the study was
- Study design
- Systematic review and meta-analysis
- Population
- A relatively strict three-concept search strategy was used, consisting of terms related to bariatric surgery, GLP-1 receptor agonists and specific drug names, and perioperative or weight-management scenarios.
- Category
- Prevention
- Maturity
- Validated
- Journal
- Zhonghua Wei Chang Wai Ke Za Zhi
Why it surfaced
Systematic review and meta-analysis with a PubMed abstract reviewed; the 7/10 score reflects conservative novelty, relevance, design-quality, and population/unmet-need assessment.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.